Delivery Order SPE2DB24D2003-SPE2DB25FXJJ4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,376.00 to supply Gemtesa 75 mg tablets (90-count packaging) with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Gemtesa 75 mg tablets (90-count packaging) with a ceiling value of $3,197.73. This firm fixed-price delivery order, which is expected to be completed by August 20, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026). The award was made through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) at a ceiling value of $2,378.33. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on August 29, 2025, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 16, 2025, by the Defense Logistics Agency's Medical Supply Chain to deliver 90-count bottles of Gemtesa 75 mg tablets under a firm fixed-price contract valued at $101,975.94. The delivery order, which is classified as a child contract under a larger indefinite delivery vehicle, carries an ultimate completion date of September 17, 2025, and is to be performed at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $4,606.47. This delivery order represents a firm fixed-price, non-set-aside contract to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $4,983.09 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units), with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Gemtesa 75 mg tablets (30-count units) with a ceiling value of $7,558.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The contract was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a $45.5K delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $8,782.31. This firm fixed-price delivery order, with an ultimate completion date of September 10, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $42,751.81. This non-set-aside delivery order is expected to be completed by August 1, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child award under the company's larger Indefinite Delivery Contract (IDC)...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXJJ4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Gemtesa 75 mg tablets (90-count packages) with a ceiling value of $40,767.56. This firm fixed-price delivery order, which must be completed by June 9, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The award was competitively procured with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving the Department of Defense and federal healthcare systems through its $999,999,999 indefinite delivery contract with DLA Troop Support Medical, which extends through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products, medical devices, and healthcare commodities to support military healthcare programs globally. Gemtesa is a medication used in treating overactive bladder, reflecting the broad therapeutic portfolio AmerisourceBergen delivers to federal medical supply chains for military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.8k | 6/6/25 |